Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
Diseases » Tuberculosis » Diagnosis
 

Diagnosis of Tuberculosis

Diagnostic Test list for Tuberculosis:

The list of medical tests mentioned in various sources as used in the diagnosis of Tuberculosis includes:

  • Chest x-ray
  • TB skin test - also called Mantoux test or purified protein derivative (PPD) test
  • Sputum test for tuberculosis
  • Lung fluid tests for tuberculosis
  • Biopsy
  • Lymph node biopsy

Tests and diagnosis discussion for Tuberculosis:

Tuberculosis, NIAID Fact Sheet: NIAID (Excerpt)

The tuberculin skin test, also known as the Mantoux test, can identify most people infected with tubercle bacilli six to eight weeks after initial exposure. A substance called purified protein derivative (PPD) is injected under the skin of the forearm and examined 48 to 72 hours later. If a red welt forms around the injection site, the person may have been infected with M. tuberculosis, but doesn't necessarily have active disease. Most people with previous exposure to TB will test positive on the tuberculin test, as will some people exposed to related mycobacteria. An important exception is people with severely weakened immune systems, such as those with HIV.

If a person has a significant reaction to the tuberculin skin test, additional methods can determine if the individual has active TB. This is sometimes difficult because TB can mimic other diseases, such as pneumonia, lung abscesses, tumors, and fungal infections, or occur along with them. In making a diagnosis, doctors rely on symptoms and other physical signs, a person's history of exposure to TB, and x-rays that may show evidence of TB infection, usually in the form of cavities or lesions in the lungs.

The physician also will take sputum and other samples, because a positive bacteriologic culture of M. tuberculosis is essential to confirm the diagnosis and determine which drugs will work against the strain of TB the patient carries. Because M. tuberculosis grows very slowly, the laboratory diagnosis requires approximately four weeks. An additional two to three weeks usually are needed to determine the drug susceptibility of the organism, making treatment decisions difficult.

Advances in Diagnosis

Recently, researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) as well as other investigators developed tests that use nucleic acid amplification to speed the diagnosis of TB from four weeks to two days. Another test in development uses luminescent chemicals from the firefly to determine, in 24 to 48 hours, which drugs can kill the TB strain a patient carries.

Treatment of Active Disease

The death rate for untreated TB patients is between 40 and 60 percent. With appropriate antibiotics, however, people with drug-susceptible cases of TB can be cured more than 90 percent of the time.

Successful management of TB depends on close cooperation between the patient and physicians and other health care workers. Patient education is essential, and many doctors opt for supervised, directly observed therapy (DOT). Treatment usually combines the drugs isoniazid (INH) and rifampin, which are given for at least six months, and pyrazinamide and ethambutol (or streptomycin), which are used only in the first two months of treatment. This treatment is referred to as short-course chemotherapy.

Therapy for MDR-TB

Treatment for MDR-TB often requires the use of a second line of TB drugs, all of which can produce serious side effects. Therapy for 18 months to two years may be necessary, and patients should receive at least three drugs to which the bacteria are susceptible.

Prevention

TB is largely a preventable disease. In the United States, prevention has focused on identifying infected individuals early especially those who run the highest risk of developing active disease and treating them with drugs in a program of directly observed therapy.

INH prevents the disease in most people in close contact with infected people or who are infected with the tubercle bacilli but who do not have active TB. The drug is given daily for six to 12 months and strict patient compliance in taking medication is essential to prevent drug-resistant strains from emerging. Adverse reactions to INH are rare, although a small percentage of patients, especially those older than 35, suffer INH-related hepatitis. Rifampin for one year is recommended for close contacts of patients with INH-resistant TB organisms.

In the United States, people with any of the following risk factors should be considered for preventive therapy, regardless of age, if they have not been previously treated for TB:

  • Close contacts of people with newly diagnosed infectious TB; (In addition, children and adolescents who react negatively to the PPD test, but who have been in close contact with infectious people within the past three months, should be considered for preventive therapy. Therapy should continue until a second skin test is done 12 weeks after their first contact with an infectious person.)
  • People with positive tuberculin skin tests and abnormal chest x-rays compatible with inactive TB (lesions caused by prior disease);
  • People whose skin test results have recently converted from negative to positive;
  • People with positive skin test reactions who also have special medical conditions known to increase the risk of TB (e.g., HIV infection, diabetes mellitus) or who are on corticosteroid therapy;
  • HIV-positive people or those suspected to be HIV-infected who now have, or had at any time in the past, positive skin test reactions, but who do not have active infection; and
  • Injection drug users who have positive skin test reactions.

In addition, people younger than 35 in the following groups should be considered for preventive therapy if they have positive skin test reactions:

  • Foreign-born people from countries where TB is common;
  • People in medically underserved, low-income groups, especially African Americans, Hispanics, and Native Americans; and
  • Residents of long-term care facilities such as prisons, nursing homes, and mental institutions.

Health care workers in frequent contact with TB patients or involved with high-risk procedures such as those that induce coughing should have a skin test every six months.

Hospitals and clinics caring for high-risk populations can take precautions to prevent the spread of TB. All patients should be taught to cover their mouths and noses when coughing or sneezing. Ultraviolet light can be used to sterilize the air, and negative pressure rooms and special filters are available, as are special respirators and masks, that filter out the droplet nuclei. Until they are no longer infectious, hospitalized TB patients should be isolated in rooms with controlled ventilation and air flow.

More Effective Vaccines are Needed

In those parts of the world where the disease is common, a vaccine composed of live, attenuated (weakened) mycobacteria from cows (M. bovis, called bacillus Calmette-Guerin [BCG]) is given to infants as part of the immunization program recommended by the World Health Organization (WHO). In infants, BCG prevents the spread of M. tuberculosis within the body, but does not prevent initial infection.

In adults, the effectiveness of BCG has varied widely in large-scale studies. In addition, positive skin test reactions occur in people who have received BCG vaccine, thus limiting the effectiveness of the PPD skin test to identify new infections. As a result, BCG is not recommended for general use in the United States. Because of BCG's limitations, more effective vaccines are needed.

TB and HIV Infection

WHO estimates that 4.4 million people worldwide are coinfected with TB and HIV. By the year 2000, TB will claim 1 million lives annually among the HIV-infected, WHO projects, making TB the leading cause of death in HIV-infected individuals. In the United States, an estimated 100,000 HIV-infected people also carry M. tuberculosis, according to CDC.

TB frequently occurs early in the course of HIV infection, often months to years before other opportunistic infections such as Pneumocystis carinii pneumonia. TB may be the first indication that a person is HIV-infected, and often occurs in areas outside the lungs, particularly in the later stages of HIV disease.

In the United States, people coinfected with TB and HIV develop active TB at a rate of about 8 percent each year. By comparison, otherwise healthy individuals infected with M. tuberculosis have a 10 percent lifetime risk of developing active TB. People with HIV also are at greater risk of having a new infection progress directly to active disease.

MDR-TB in people coinfected with HIV appears to have a more rapid and deadly disease course than seen in patients with MDR-TB who are otherwise healthy.

Diagnosing TB in HIV-infected people is often difficult. These patients frequently have conditions that produce symptoms similar to those of TB, and may not react to the standard tuberculin skin test because their immune systems are suppressed. Although investigators have hypothesized that a two-stage TB skin test might be more reliable than a single-stage test in HIV-infected individuals, a recently completed NIAID study found this not to be the case.

X-rays, sputum smears, and physical exams may also fail to provide an indication of TB infection in HIV-infected individuals. As a consequence, doctors must often decide to begin anti-TB therapy in HIV-infected people suspected of having active TB while waiting for the results of cultures of sputum or other specimens.

NIAID Research Agenda for Tuberculosis

NIAID, the lead institute for TB research at the National Institutes of Health, supports more than 100 research projects related to TB. In fiscal year 1999, NIAID will devote an estimated $40 million to TB research.

NIAID has a comprehensive TB research agenda that supports the following:

  • Studies of the epidemiology and natural history of TB.
  • Basic research into the biology of TB and the host immune response to M. tuberculosis.
  • The development of new tools to diagnose TB.
  • The development of new drugs or new ways to deliver standard drugs.
  • Clinical trials of anti-TB therapies.
  • The development of new vaccines to prevent TB.
  • Training to increase the number of TB researchers.
  • New ways to educate health care workers and the public about TB prevention.

This multi-disciplinary program draws on the Institute's expertise in immunology and microbiology, as well as its capabilities in drug and vaccine development honed as part of the research effort in AIDS and other infectious diseases.

(Source: excerpt from Tuberculosis, NIAID Fact Sheet: NIAID)

Tuberculosis, NIAID Fact Sheet: NIAID (Excerpt)

Recently, researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) as well as other investigators developed tests that use nucleic acid amplification to speed the diagnosis of TB from four weeks to two days. Another test in development uses luminescent chemicals from the firefly to determine, in 24 to 48 hours, which drugs can kill the TB strain a patient carries. (Source: excerpt from Tuberculosis, NIAID Fact Sheet: NIAID)

Tuberculosis: NWHIC (Excerpt)

A TB skin test is the only way to find out if you have TB infection. You can get a skin test at the health department or at your doctor's office. (Source: excerpt from Tuberculosis: NWHIC)

Diagnosis of Tuberculosis: medical news summaries:

The following medical news items are relevant to diagnosis and misdiagnosis issues for Tuberculosis:

 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise